InsidersTradesSigma
Follow the GreenLight Biosciences Holdings, PBC share price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Food & Agriculture sector, GreenLight Biosciences Holdings, PBC has recorded 56 reports. The latest transaction was reported on 27 July 2023 (J). Among the most active insiders: Morningside Venture Investments Ltd. Every trade is free.
56
Insider Decl.
n/a
Thresholds
€36m
3 ops.
Buy Volume
n/a
2 ops.
Sell Volume
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 27 July 2023
Declarations56 total
1,275,510.204 shares100.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001981009-23-000001:0
25,510.204 shares100.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001981009-23-000002:0
25,510.204 shares100.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001981009-23-000003:0
9,809,895 sharesCommon Stock, par value $0.0001 per shareSEC:0000950170-23-035015:0
1,000,000 sharesCommon Stock, par value $0.0001 per shareSEC:0000950170-23-034612:0
2,551,020 sharesCommon Stock, par value $0.0001 per shareSEC:0001567619-23-006692:0
47,000 sharesCommon Stock, par value $0.0001 per shareSEC:0001980452-23-000001:0
896,058 shares@ US$0.30100.0% of flowCommon StockSEC:0000950170-23-034844:0
2,697 sharesCommon Stock, par value $0.0001SEC:0001980543-23-000001:0
1,816,746 sharesCommon Stock, par value $0.0001 per shareSEC:0001062993-23-015348:0
292,186 sharesCommon Stock, par value $0.0001 per shareSEC:0001979877-23-000003:0
63,775 sharesCommon StockSEC:0000899243-23-017542:0
1,520,408 sharesCommon Stock, par value $0.0001 per shareSEC:0001980769-23-000003:0
14,886 sharesCommon Stock, par value $0.0001 per shareSEC:0001980454-23-000001:0
569,423 sharesCommon Stock, par value $0.0001 per shareSEC:0001817857-23-000004:0
305,314 shares@ US$0.30100.0% of flowCommon StockSEC:0000950170-23-034927:0
172,500 sharesCommon Stock, par value $0.0001 per shareSEC:0000950170-23-034873:0
29,798 sharesCommon StockSEC:0000950170-23-034853:0
3,189,151 sharesCommon StockSEC:0001104659-23-084296:0
500,890 sharesCommon Stock, par value $0.0001 per shareSEC:0001761971-23-000005:0
6,489,242 sharesGreenlight Biosciences common stockSEC:0001213900-23-060014:0
569,423 sharesCommon Stock, par value $0.0001 per shareSEC:0001817857-23-000003:0
109,218 shares@ US$0.30100.0% of flowCommon StockSEC:0000950170-23-034871:0
5,818,575 sharesCommon Stock, par value $0.0001 per shareSEC:0000950170-23-034900:0
1,520,408 sharesCommon Stock, par value $0.0001 per shareSEC:0001980769-23-000002:0
25 of 56 declarations
About GreenLight Biosciences Holdings, PBC
GreenLight Biosciences Holdings, PBC (ticker: GRNA) is a U.S.-listed agricultural biotechnology company traded on the NASDAQ market in the United States. Headquartered in Lexington, Massachusetts, United States, the company was founded in 2008 and has built its strategy around a proprietary cell-free RNA production platform. GreenLight’s core thesis is that RNA can be manufactured at scale and deployed as a precise biological tool for agriculture and related life-science applications, offering a differentiated alternative to conventional chemical inputs. The company’s business is centered on the research, development, manufacturing, and commercialization of RNA-based products for plant protection and pollinator health. GreenLight uses RNA interference (RNAi) to target specific pests or pathogens with high selectivity. Its first commercial products are Calantha™, an EPA-registered bioinsecticide for Colorado potato beetle control in potatoes, and Norroa™, an RNA-based treatment for varroa mites in honeybees. The company is also advancing a broader pipeline across insecticides, fungicides, and herbicides, including programs aimed at fungal diseases in grapes and strawberries and at herbicide-resistant weeds. From a competitive standpoint, GreenLight positions itself as an early leader in applied RNA for agriculture. Its differentiation lies in combining biological precision, environmental compatibility, and industrial-scale RNA manufacturing know-how. The company emphasizes its patent portfolio, scale-up capabilities, and years of technical development as key strategic assets. That said, the investment profile remains that of an emerging commercialization-stage biotech: execution risk, regulatory dependence, and adoption risk remain central considerations, even as the company begins to convert its platform into marketable products. GreenLight’s operating footprint is mainly in the United States, with facilities around Boston, Massachusetts, plus manufacturing and R&D sites in Rochester, New York, Durham, North Carolina, and additional research operations in Spain. Recent notable developments include the EPA registration and launch of Norroa in 2025, the commercial rollout of Calantha, and the October 2025 filing of regulatory dossiers in the United States, the European Union, and Brazil for an RNA-based fungicide targeting grape powdery mildew. For investors, GRNA is best viewed as a thematic growth name in agricultural innovation: potentially high upside if the RNA platform scales, but still carrying substantial clinical-style commercialization and regulatory risk.
